Iron Balance Study of DFO and GT56-252 in Patients With Transfusional Iron Overload Secondary to Beta-Thalassemia

Evaluation of Subcutaneous Desferrioxamine as Treatment for Transfusional Hemochromatosis

NCT00000595 ·Status: COMPLETED ·Phase: PHASE2

Combination Deferasirox and Deferiprone for Severe Iron Overload in Thalassemia

NCT01709032 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Evaluating Use of Deferasirox as Compared to Deferoxamine in Treating Cardiac Iron Overload

NCT00600938 ·Status: COMPLETED ·Phase: PHASE2

Safety and Pharmacokinetic Study of Escalating Multiple Doses of an Iron Chelator in Patients With Iron Overload

NCT01039636 ·Status: COMPLETED ·Phase: PHASE1

Clinical Trial of Deferasirox Combination Treatment With Deferiprone In Thalassaemia Patients

NCT02198508 ·Status: COMPLETED ·Phase: NA

Safety & Efficacy of ICL670 vs. Deferoxamine in Beta-thalassemia Patients With Iron Overload Due to Blood Transfusions

NCT00061750 ·Status: COMPLETED ·Phase: PHASE3

Extension Study of the Efficacy and Safety of Deferasirox Treatment in Beta-thalassemia Patients With Transfusional Hemosiderosis (Study Amended to 2-year Duration)

NCT00171301 ·Status: COMPLETED ·Phase: PHASE4

Extension Study of Iron Chelation Therapy With Deferasirox in Patients With Transfusional Iron Overload

NCT00379483 ·Status: COMPLETED ·Phase: PHASE2

Phase I Study to Examine the Effect of Deferasirox on Renal Hemodynamics in β-thalassemia Patients With Transfusional Iron Overload

NCT00560820 ·Status: COMPLETED ·Phase: PHASE1

Safety and Efficacy of Deferasirox in Combination With Desferoxamine in β-thalassaemia Patients With Severe Cardiac Iron Overload

NCT01459718 ·Status: TERMINATED ·Phase: PHASE2

Study of Deferasirox for Treatment of Transfusional Iron Overload in Myelodysplastic Patients

NCT00110266 ·Status: COMPLETED ·Phase: PHASE2

Evaluating the Efficacy of Deferasirox in Transfusion Dependent Chronic Anaemias (Myelodysplastic Syndrome, Beta-thalassaemia Patients) With Chronic Iron Overload

NCT00564941 ·Status: COMPLETED ·Phase: PHASE4

An Algorithm to Start Iron Chelation in Minimally Transfused Young Beta-thalassemia Major Patients

NCT02173951 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3

A 4-year Extension Study to Core 1-year Study of Iron Chelation Therapy With Deferasirox in β-thalassemia Major Pediatric Patients With Transfusional Iron Overload.

NCT00390858 ·Status: COMPLETED ·Phase: PHASE2

Efficacy and Safety Study of Deferasirox in Patients With Non-transfusion Dependent Thalassemia

NCT01709838 ·Status: COMPLETED ·Phase: PHASE4

Safety and Acceptability of Deferiprone Delayed Release Tablets in Patients With Systemic Iron Overload

NCT03802916 ·Status: COMPLETED ·Phase: PHASE2

Combination Iron Chelation Therapy

NCT00004982 ·Status: COMPLETED ·Phase: PHASE1

Efficacy and Safety of Efficacy and Safety of Continued Iron Chelation Therapy In Poly-transfused Thalassemia Patients With Low Serum Ferritin (< 500 ng/ml)

NCT01996683 ·Status: UNKNOWN ·Phase: NA

Safety and Efficacy of Deferasirox (ICL670) in Patients With Iron Overload Resulting From Hereditary Hemochromatosis

NCT00395629 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Study With Deferiprone and/or Desferrioxamine in Iron Overloaded Patients

NCT00350662 ·Status: COMPLETED ·Phase: PHASE3

Study for the Treatment of Transfusional Iron Overload in Myelodysplastic Patients

NCT00117507 ·Status: COMPLETED ·Phase: PHASE4

Safety and Pharmacodynamic Study of an Oral Iron Chelator Given for 6 Months to Patients With Iron Overload

NCT01186419 ·Status: COMPLETED ·Phase: PHASE2

Study of Deferasirox Relative to Subcutaneous Deferoxamine in Sickle Cell Disease Patients

NCT00110617 ·Status: COMPLETED ·Phase: PHASE2

Evaluation of the Safety, Tolerability, Pharmacokinetics (PK) and Effects on Liver Iron Concentration of ICL670 Relative to Deferoxamine(DFO).

NCT01090323 ·Status: COMPLETED ·Phase: PHASE2

A Study Assessing the Efficacy and Safety of Deferasirox in Patients With Transfusion-dependent Iron Overload

NCT00171821 ·Status: COMPLETED ·Phase: PHASE3